NEWTON, Mass.--(BUSINESS WIRE)--Matritech (Amex: MZT), a leading developer of protein-based diagnostic products for the early detection of cancer announced today that it has signed agreements for the manufacture and distribution of Matritech’s NMP22® BladderChek® Test with Inverness Medical Innovations, Inc. (Amex: IMA), a leading manufacturer and supplier of rapid diagnostic products for the consumer and professional markets. Inverness will begin supplying the point-of-care urine test that is used in the diagnosis of bladder cancer. Under a separate agreement, Inverness will become the exclusive U.S. distributor of the test to be sold through over-the-counter retail channels.
